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DOPAG protein-coupled receptors (GPCRs) are the target ofmany drugs prescribed for humanmedicine and are there-
fore the subject of intense study. It has been recognized that compounds called allostericmodulators can regulate
GPCR activity by binding to the receptor at sites distinct from, or overlapping with, that occupied by the
orthosteric ligand. The purpose of this study was to investigate the nature of the interaction between putative al-
losteric modulators and Ste2p, a model GPCR expressed in the yeast Saccharomyces cerevisiae that binds the
tridecapeptide mating pheromone α-factor. Biological assays demonstrated that an eleven amino acid α-factor
analog and the antibiotic novobiocin were positive allosteric modulators of Ste2p. Both compounds enhanced
the biological activity ofα-factor, but did not competewithα-factor binding to Ste2p. To determine if novobiocin
and the 11-mer shared a common allosteric binding site, a biologically-active analog of the 11-mer peptide
([Bio-DOPA]11-mer) was chemically cross-linked to Ste2p in the presence and absence of novobiocin. Immuno-
blots probing for the Ste2p–[Bio-DOPA]11-mer complex revealed that novobiocin markedly decreased cross-
linking of the [Bio-DOPA]11-mer to the receptor, but cross-linking of the α-factor analog [Bio-DOPA]13-mer,
which interacts with the orthosteric binding site of the receptor, was minimally altered. This ﬁnding suggests
that both novobiocin and [Bio-DOPA]11-mer compete for an allosteric binding site on the receptor. These results
indicate that Ste2p may provide an excellent model system for studying allostery in a GPCR.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
G protein-coupled receptors (GPCRs) represent the largest family of
membrane proteins that sense environmental cues and send signals
across the plasma membrane to initiate cellular responses [1]. This
class of proteins, when mutated or inappropriately expressed, may be
linked to a variety of disease states thus making them prime targets
for prescribed drugs to treat ailments such as cardiovascular disease,
allergies, asthma, and even some types of cancer [2]. These receptors
consist of sevenmembrane-spanning domains, which transduce signals
via the activation of heterotrimeric guanine nucleotide binding proteins
and/or other intracellular proteins [1,3]. Signal transduction relies on
the activation of the GPCR by the binding of its cognate ligand to a spe-
ciﬁc orthosteric site of the receptor [4]. In addition, receptor activationM409 Walters Life Sciences,
tates. Tel.: +1 865 974 3006;
r at the College of Staten Island.can be modulated by ligands which bind to the receptor at non-
canonical sites. These allosteric ligands bind to sites distinct from the
orthosteric site on GPCRs and, depending on the speciﬁc ligand, can
serve to either enhance or inhibit the biological response induced by
the orthosteric ligand [5]. Allosteric modulators that inhibit orthosteric
signaling are referred to as negative allosteric modulators (NAMs),
while those that enhance signaling by the orthosteric ligand are called
positive allosteric modulators (PAMs). Additionally, some allosteric
ligands have the capability of not only modulating the efﬁciency of
receptor activation, but can also activate the receptor in the absence of
an orthosteric ligand [5].
While there is selective pressure to maintain the structural charac-
teristics of the orthosteric binding site for a particular function of a
GPCR, the regions of the receptor which serve as allosteric binding
sites are not under this constraint. Thus, allosteric binding sites can be
used to selectivelymodulate one speciﬁc receptor subtype over another
[5–7]. Given the physiological importance of GPCRs, they are an ideal
target for therapeutic agents [8,9]. In addition, allosteric modulators
have a limit on their maximal degree of enhancement or inhibition
of the receptor, which also make them less prone to target related
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to selectively modulate speciﬁc GPCR subclasses will promote the
development of drugs targeting speciﬁc receptors with minimal side-
effects.
The yeast Saccharomyces cerevisiae has been used as a model organ-
ism for GPCR research due to the robust genetic and molecular tools
available to manipulate protein expression, and mutagenesis. This
yeast expresses an endogenous GPCR, Ste2p, which is essential for
pheromone-induced sexual conjugation of this single cell eukaryote.
The orthosteric ligand responsible for triggering this pathway is the
13-mer peptide α-factor (WHWLQLKPGQPMY) (Fig. 1A) [10]. Ste2p is
one of only two GPCRs expressed in MATa yeast cells, thus providing a
convenient and controllable system for the study of GPCR structure
and function [11]. S. cerevisiae also provides a model system for the
expression of certain vertebrate GPCR making ﬁndings uncovered and
methods developed with Ste2p relevant to medically important targets
[12,13].
In a previous report [14]we described amodulator of Ste2p function,
an 11-mer analog of α-factor lacking the C-terminal Met and Tyr
residues (WHWLQLKPGQP) (Fig. 1B). This 11-mer peptide had no
innate biological activity, did not compete for binding with α-factor,
and did not inﬂuence the afﬁnity of the receptor for the ligand in a
wild-type yeast strain. However, this ligand did enhance the biological
activity of the native ligand α-factor and was a very weak agonist in a
yeast mutant that was supersensitive to the ligand. Originally, we ap-
plied the term “synergist” to this compound [14] but it more correctly
ﬁts the deﬁnition of a positive allosteric modulator, or PAM. Inmost cir-
cumstances, PAMs have little or no structural similarity to the
orthosteric ligand. Interestingly, in this instance the 11-mer is a
C-terminally truncated version of α-factor. The question we are
addressing in this report is how does this peptide exert its effect: by
binding to a distinct allosteric site, or by interaction at a sitewhich over-
laps the orthosteric site without competing for binding. To this end, weFig. 1. A. Peptides used in this study: α-factor, 11-mer, and [Bio-DOPA]11-mer containing DO
(DOPA). C. Structure of novobiocin.have synthesized anα-factor analog, [Bio-DOPA]11-mer, a novel modi-
ﬁed 11-mer (Fig. 1A) that allowed for DOPA-mediated chemical cross-
linking of the analog to the receptor. Previously we used a similarmeth-
odology to cross-link a full-length, DOPA-modiﬁed α-factor into Ste2p
in order to determine the pheromone binding site in the receptor [15].
In order to detect the receptor–ligand complex, biotinylaminocaproate
(BiotinACA) was tagged onto the Lys7 position of the ligand. Immuno-
blots containing the cross-linked Ste2p enriched samples were probed
with NeutrAvidin-HRP to detect the [Bio-DOPA]α-factor bound to
Ste2p [15]. Our intent in this report was to use the same technique to
interrogate the interaction of the [Bio-DOPA]11-mer with the receptor.
To increase the scope of these studies, we have coupled our investi-
gation of the 11-mer to that of novobiocin (Fig. 1C), a compound known
as a coumarin antibiotic that inhibits bacterial DNA gyrase and also
binds eukaryotic Hsp90 with high afﬁnity. Previously, novobiocin,
which has no structural similarity to α-factor, the orthosteric ligand
(Fig. 1A),was shown to activate the Ste2p-mediated signal transduction
pathway when added to a supersensitive mutant strain [16,17]. We
have determined that novobiocin had no activity in a wild-type strain
of yeast, but in the presence of α-factor, novobiocin enhanced the
biological response of the orthosteric ligand resulting in PAM activity.
We also found that novobiocin competed with the [Bio-DOPA]11-mer
for cross-linking to Ste2p, but did not compete for binding of α-factor
leading us to hypothesize that these two structurally distinct com-
pounds, novobiocin and the 11-mer derivative, may bind to the same,
perhaps overlapping, allosteric site on Ste2p.
2. Experimental procedures
2.1. Strains and media
S. cerevisiae LM102 (MATa, bar1, his4, leu4, trp1, met1, ura3, FUS1–
lacZ::URA3, ste2-dl) [18] transformed with the plasmid pBEC2 wasPA and biotinylaminocaproate (BiotinACA). B. Structure of L-3,4-dihydroxyphenylalanine
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test for biological activity. The plasmid pBEC2 encodes a Cys-less
(C59S, C252S) Ste2p bearing C-terminal FLAG (FT) and His (HT) epitope
tags [19].Wewill refer to this particular construct as Ste2p-FT-HT in this
report. The protease deﬁcient strain BJS21 (MATa, prc1-407, prb1-1122,
pep4-3, leu2, trp1, ura3-52, ste2::Kan) [20] bearing the pBEC2 plasmid
was used for all DOPA cross-linking experiments. Both strains were
grown in a synthetic medium lacking tryptophan (MLT) [21] to main-
tain selective pressure to retain the Trp-based pBEC2 plasmid.
2.2. Membrane preparation
BJS21 cells expressing Ste2p-FT-HT receptor were grown overnight
with shaking in 200 ml of MLT. Cells were harvested in a table top cen-
trifuge, washed three times, and resuspended in a small volume of
HEPES/EDTA (50 mM HEPES, 5 mM EDTA, pH 7.5). The cells were har-
vested by centrifugation (5000 rpm for 30 s) in microcentrifuge tubes.
Subsequent steps were performed at 4 °C unless otherwise stated. The
supernatant was removed, glass beads (0.5 mm diameter, 200 μl) and
HEPES/EDTA (200 μl) added to the tube. Cells were shaken in a
FastPrep-24 (MP Biomedicals, Santa Ana, CA) homogenizer for one set
of cycles (1 min on, 2 min off, repeated a total of three times). Cells
were chilled on ice for 15 min and then subjected to a second set of
homogenization cycles. Unbroken cells and glass beads were removed
by centrifugation (2000 rpm for 5min), and the supernatant was trans-
ferred to a cleanmicrocentrifuge tube.Membraneswere harvested from
the supernatant by centrifugation (13,000 rpm, 30min). Theﬁnalmem-
brane pellet was homogenized and resuspended in NE buffer (20 mM
HEPES, 20% glycerol, 100 mM KCl, 12.5 mM EDTA, pH 9). Membrane
concentration was determined using the BioRad Protein Assay (BioRad,
Hercules, CA).
2.3. Synthesis and cross-linking of [Bio-DOPA]11-mer
Synthesis of [DOPA1, K7 (BiotinACA), desM12desY13] α-factor ([Bio-
DOPA]11-mer) and [DOPA1, K7 (BiotinACA)] α-factor ([Bio-DOPA]13-
mer) was completed using methodology similar to that previously
described [15]. Brieﬂy, the assembly of the peptide chain and incorpora-
tion of 3,4-dihydroxyphenylalanine (DOPA) in the 11-mer peptidewere
conducted by automated solid-phase synthesis on a L-prolyl-2-
chlorotrityl resin (0.7 mmol/mg) using standard Fmoc protocols with
HBTU (N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexa-
ﬂuorophosphate), O-(benzotriazol-1-yl)-(N,N,N′,N′-tetramethyluronium
hexaﬂuorophosphate)/HOBt (hydroxybenzotriazole) catalyzed single
coupling reactions on an Applied Biosystems 433A automated peptide
synthesizer. Fmoc-DOPA-OH was used without side-chain protection
and the weight gain of the resin was 100% ± 10%. After drying the resin
was split 1:2 and the Fmoc group was cleaved from one third of the
resin to give DOPA-HWLQLKPGQP-resin.
Both the free 11-mer and the α-Fmoc protected 11-mer were
cleaved from the resin using of 0.75 g phenol, 0.5 ml water, 0.5 ml
thioanisole, 0.25 ml 1,2-ethanedithiol and 0.1 ml triisopropylsilane in
10 ml triﬂuoroacetic acid for 1.5 h. The approximate yield of assembly
and resin cleavage steps was 85% based on the initial resin loading.
The crude 11-mer (DOPA-HWLQLKPGQP; 31 mg) was puriﬁed by
HPLC using a C18 DeltaPak column to give 17.1 mg (55% recovery) of
a homogeneous peptide with a MW of 1382.5 (calc 1382.6). The
Fmoc-DOPA-HWLQLKPGQP peptide (104 mg) was puriﬁed similarly
to give 33 mg (31.7% recovery) of homogeneous peptide with a MW
of 1604.8 (calc. 1604.84). Biotinylaminocaproate was attached to Lys7
of the Fmoc-protected peptide (22.7 mg) in a solution phase reaction
through hydroxysuccinimide-mediated amide bond formation [15] in
a dimethylformamide/sodium borate medium, which was ﬂushed
with argon, at 4 °C for 1 h. The Fmocwas removed by the addition of pi-
peridine, the reaction quenched by HCl and the ﬁltered medium was
loaded on a preparative HPLC to give 18.8 mg of pure ([Bio-DOPA]11-mer; DOPA-HWLQLK(BiotinACA)PGQP, MW 1722.0, calc. 1722.1)
representing a 77% yield of coupling, Fmoc removal, and puriﬁcation.
TheDOPAmoietywas activatedwith periodate based on themethod
of Burdine et al. [22] for cross-linking of the peptide into Ste2p, and bi-
otin was used for avidin-linked detection of the ligand in the receptor–
ligand complex. For cross-linking of the [Bio-DOPA]11-mer into Ste2p,
freshly prepared membrane samples (~4.5 mg) were adjusted to a
ﬁnal volume of 1 ml in NE buffer in siliconized microcentrifuge tubes
and incubated in the presence or absence of [Bio-DOPA]11-mer
(85 μM) plus or minus novobiocin (5 mM or 50 mM; Sigma, St. Louis,
MO) for 2 h at 4 °C with end-over-end mixing. Novobiocin was freshly
prepared in NE buffer immediately before use in all experiments. For
the crosslinking of [Bio-DOPA]13-mer, membranes were incubated
with 10 μM of this 13-residue peptide in the presence or absence
novobiocin (5mMor 50mM). To initiate cross-linking of DOPA, a fresh-
ly prepared sodium periodate solution (50 mM) was added to a ﬁnal
concentration of 2 mM, and the tubes were incubated in the dark
at room temperature for 30 min with occasional vortexing. The
membranes were then harvested by centrifugation (13,000 rpm,
30 min, 4 °C), resuspended in 3.0 ml solubilization buffer (TBS
[50 mM Tris HCl, pH 7.4, 150 mM NaCl], 1 mM EDTA, 2.5% Triton X-
100) supplemented with protease inhibitors (phenylmethylsulfonyl
ﬂuoride 1.7 ng/μl, pepstatin A 1 ng/μl, and leupeptin 1 ng/μl), and then
incubated in a 15 ml conical tube overnight at 4 °C with end-over-end
mixing.
2.4. Ste2p enrichment and immunoblotting
Following overnight incubation, the solubilized samples were
cleared by centrifugation (13,000 rpm, 30 min, 4 °C). The resulting su-
pernatant was combined with 100 μl FLAG resin (Sigma, St. Louis, MO)
prepared by washing with TBS (150 mM NaCl, 50 mM Tris HCl,
pH 7.4), according to the manufacturer's instructions, and incubated
overnight with end-over-end mixing at 4 °C. Upon completion of the
incubation interval, the tubes were placed on ice, and the beads were
allowed to settle by gravity for 15 min, then centrifuged for 30 s at
3000 rpm in a table top centrifuge at 4 °C to collect beads remaining
on the sides of the tube. The supernatant was removed, and the beads
were washed with 1% Triton-X buffer (TBS [50 mM Tris HCl, pH 7.4,
150mMNaCl], 1 mM EDTA, 1% Triton X-100) followed by three washes
with TBS, each time allowing the beads to settle by gravity followed by
centrifugation as described. Material bound to the FLAG beads was ex-
tracted in 100 μl of non-reducing SDS sample buffer (200 mM Tris,
pH 6.8, 2% SDS, 40% glycerol) by mixing at room temperature for
5 min, and pelleting the beads for 30 s at 10,000 rpm. The supernatant
was collected, and protein concentrations were measured using the
detergent-compatible protein assay (BioRad, Hercules, CA). Samples
were fractionated by gel electrophoresis (10% SDS-PAGE), and blotted
onto Immobilon-P (Millipore, Billerica, MA). To probe for the FLAG epi-
tope, blots were blocked in 5%milk in TBS and incubated overnightwith
FLAG M2 antibody (Sigma, St. Louis, MO) diluted 1:20,000 in TBS plus
0.1% Tween 20 (TBST). The FLAG blot was washed and then incubated
with a goat anti-mouse HRP conjugate secondary antibody (Promega,
Madison, WI) diluted 1:15,000 in TBST for 3 h. To probe for biotin,
blotswere blocked in 3%BSA and incubated overnightwithNeutrAvidin
HRP conjugate (Pierce, Rockford, IL) diluted 1:10,000 dilution in TBST.
Upon completion of the incubation intervals, FLAG and biotin blots
were washed and incubated with West Pico chemiluminescent detec-
tion reagent (Pierce, Rockford, IL) for imaging on the ChemiDoc XRS
photodocumentation system (BioRad, Hercules, CA). Band densities
were measured using the volume tools of the Image Lab software
(version 3.0 build 11, Bio-Rad, Hercules CA) and used to normalize the
NeutrAvidin HRP signal (biotinylation) to the FLAG signal (total
Ste2p) to control for sample to sample variation in protein concen-
tration. The results were expressed as percent control, whichwas deter-
mined from the signal in the absence of novobiocin. These experiments
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representative blots are presented.
2.5. Growth arrest assay
LM102 cells expressing Ste2p-FT-HT were grown overnight (~16 h)
at 30 °C inMLTwith shaking. The cellswere harvested by centrifugation,
washed three timeswith sterilewater and adjusted to a ﬁnal concentra-
tion of either 1 or 3 × 106 cells/ml. Onemilliliters of cell suspensionwas
combinedwith 3.5mlmolten Noble agar (1.1%, tempered to 50 °C), and
themixture was overlayed ontoMLT plates. For some experiments cells
were combined with tempered Noble agar (1.1%) in the absence or
presence of 2.2 mg of novobiocin, and the mixture was overlayed onto
MLT plates. Sterile ﬁlter disks impregnated with different amounts of
peptide solution, as indicated for each speciﬁc experiment, were placed
on the overlay and the plates incubated at 30 °C for 24 to 48 h and
photographed using the BioRad ChemiDoc XRS photodocumentation
system. These growth arrest assays were repeated three times with
the area of the halo including the disk usually within ±15% in each of
the assays.
2.6. FUS1–lacZ assay
FUS1–lacZ activity was determined by the method of Hoffman [23].
LM102 cells expressing or lacking Ste2p-FT-HT were grown overnight
(~16 h) at 30 °C with shaking. The cells (5 ml) were harvested by cen-
trifugation (4000 rpm, 5 min.) and re-suspended in 1 ml of MLT. The
cells were then diluted 1:20 into 5 ml of fresh MLT and cultured for
4 h at 30 °C. Cells (450 μl) were dispensed into 1.5 ml siliconized
tubes, supplemented with 50 μl peptide or novobiocin solution (at the
concentrations indicated for each experiment) and incubated at 30 °C
for 90 min with shaking. Upon completion of the incubation interval,
90 μl of cells was dispensed into each of 4 wells (quadruplicate each
sample) of a 96 well plate. The optical density (OD600) of each sample
was determined using a Synergy-4 96-well plate reader (Bio-Tek
Instruments, Inc., Winooski, VT). A working solution of ﬂuorescein di-
β-galactopyranoside (FDG;Molecular Probes, Inc., Eugene, OR)waspre-
pared by mixing equal amounts of fresh Solution A (40 μM FDG in
25 mM PIPES buffer, pH 7.2) and Solution B (0.5% Triton X-100 in
250 mM PIPES buffer, pH 7.2). The FDG working solution (20 μl) was
added to each well to initiate the reaction, and the plate was gently
mixed and incubated at 37 °C for 90 min in the dark. Measurement of
β-galactosidase activity was determined by measuring ﬂuorescence
(excitation of 485 nm, emission of 530 nm) with the Synergy-4 reader.
Background ﬂuorescence measured in the absence of cells was
subtracted from resulting values, and measurements were divided by
OD600 values.
2.7. Binding assays
The saturation and competition binding assays were carried out
using [3H]α-factor prepared as described [24]. LM102 cells expressing
or lacking Ste2p-FT-HT receptor were grown overnight in MLT at 30 °C
with shaking. Cells were washed with water and resuspended in
YM1imedium (5 g yeast extract, 10 g peptone, 10 g succinic acid, 6 g so-
dium hydroxide, 10 g glucose, 0.64 g sodium azide, 0.94 g potassium
ﬂuoride, 3.8 g Tosyl-L-Arginine Methyl Ester (TAME), and 5 g of BSA
per 1 l) at a ﬁnal concentration of 3 × 107 cells/ml. For the competition
binding assays, cells (810 μl) were combinedwith 90 μl YM1i containing
50 nM 3H α-factor plus or minus 10× competitor (cold α-factor or no-
vobiocin). The ﬁnal concentration of 3H α-factor in the binding assay
was 5 nM and the competitor concentrations are speciﬁed for each ex-
periment. The cells were incubated in the binding assay mixture for
30 min on ice, then dispensed (4 × 200 μl) into wells of a 96-well
plate. The wells were harvested using a Skatron Cell Harvester (Skatron
Instruments, Sterling, VA) and radioactivity retained on the ﬁlterdetermined by liquid scintillation counting. Speciﬁc binding was
determined by subtracting radioactivity associated with LM102 lacking
Ste2-FT-HT (background) from the counts of the strain expressing the
receptor (total counts). The data were analyzed by non-linear regres-
sion for single site binding usingGraphPadPrism6 (GraphPad Software,
La Jolla, CA).
For the saturation binding assay, cells were resuspended in YM1i at a
concentration of 3 × 107 cells/ml and dispensed into siliconized tubes
(810 μl). To each tube, 90 μl of a 10× [3H]α-factor stock in the presence
or absence of novobiocin was added. The ﬁnal concentration of [3H]α-
factor ranged from 1.5 to 50 nM, and novobiocin was present at a ﬁnal
concentration ranging from 10−4 M to 10−8 M. The samples were incu-
bated on ice for 30 min and processed as described above to determine
the speciﬁc amount of radioactivity associated with each sample and
subsequent data analysis. Statistical signiﬁcance between Kd and
Bmax values calculated at the various novobiocin concentrations was
determined using GraphPad Prism6 extra sum of squares F-test
(GraphPad Software, La Jolla, CA).
3. Results
3.1. 11-mer, [Bio-DOPA]11-mer, and novobiocin exhibit enhancement of
α-factor activity in both growth arrest and FUS1–lacZ assays
The 13-residue α-factor pheromone (Fig. 1A) is the natural ligand
for the pheromone receptor Ste2p. Binding of the pheromone to Ste2p
initiates the signal transduction pathway resulting in growth arrest,
cell morphogenesis, and gene induction in preparation for sexual conju-
gation of S. cerevisiae [25]. The 11-mer (Fig. 1A), a C-terminally truncat-
ed version of the α-factor, was previously reported to have no innate
biological activity when added to wild-type cells expressing Ste2p, but
this analog did promote an enhancement of the growth arrest in
response to the natural ligand [14]. We re-tested the effect of the
11-mer on a different S. cerevisiae strain expressing a modiﬁed Ste2p
receptor (Cys-less and epitope tagged) and found, similar to the previ-
ous results, that growth arrest was greatly increased when combining
α-factor with the 11-mer (Fig. 2A). At a dosage of 0.1 μg/disk, α-factor
produced a small ‘halo’ or zone of growth inhibition (86 ± 6 mm2,
including the area of the disk), while the 11-mer (15 μg/disk) had no bi-
ological activity. In contrast, co-incubation with α-factor and 11-mer
(0.1 μg and 15 μg/disk, respectively) yielded a large halo (382 ±
36 mm2) thus indicating an enhanced growth arrest in response to
the presence of both peptides. Enhancement of FUS1–lacZ reporter
gene activity was likewise observed when combining α-factor with
11-mer or the [Bio-DOPA]11-mer (Fig. 2B). In the absence of α-factor,
the 11-mer did not stimulate reporter gene activity over control levels
(Fig. 2B). Upon incubation with both α-factor (50 nM) and 11-mer
(30 μM) a 2.5 fold increase in reporter gene activity was observed.
Taken together, the results of the growth arrest and FUS1–lacZ reporter
gene assays suggest that the 11-mer is functioning as a positive alloste-
ric modulator of α-factor activity.
To further explore the interaction between the 11-mer and Ste2p,
we synthesized an analog of the 11-mer ([Bio-DOPA]11-mer)
(Fig. 1A). Subsequent to activation by periodate, this ligand cross-links
to proteins, and the cross-linked complex detected by virtue of the bio-
tin tag on the ligand. This compound was tested for biological activity,
and like the 11-mer, the [Bio-DOPA]11-mer analog has no intrinsic bio-
logical activity as assessed by growth arrest and FUS1–lacZ assay (Fig. 2A
and B). However, the [Bio-DOPA]11-mer does promote increased
growth arrest and reporter gene activity when combined with
α-factor (Fig. 2A and B). For the growth arrest response, the combina-
tion of α-factor (0.1 μg/disk) and [Bio-DOPA]11-mer (15 μg) yielded a
zone of inhibition (309 ± 27 mm2) somewhat less than that for the
combination of the 11-mer and α-factor (382 ± 36 mm2), Fig. 2A. The
allosteric effect of the 11-mer was not a consequence of the 11-mer
competing for non-speciﬁc binding of α-factor to the disk as shown
Fig. 2. A. Growth arrest assay in response to co-spotting 0.1 μg of α-factor with 15 μg of
11-mer (plate on the left), and when co-spotting 0.1 μg of α-factor with 15 μg of
[Bio-DOPA]11-mer (plate on the right). The ﬁgure shown is a representative of three rep-
licates, and halo sizes varied by less than 10%. B. Beta-galactosidase activity (FUS1–lacZ re-
porter gene assay) in response to 50 nM α-factor in the presence or absence of either
30 μM 11-mer or 30 μM [Bio-DOPA]11-mer. Results are reported as the mean ± standard
error of three determinations normalized to the response to α-factor alone (100%).
Fig. 3. A. Growth arrest assay in response to 0.1 or 0.2 μg ofα-factor in the absence (plate
on the left) or presence of 2.2 mg of novobiocin in the top agar (plate on the right). The
ﬁgure shown is a representative of three replicates, and halo sizes varied by less than
10%. B. Effect of novobiocin on FUS1–lacZ reporter gene activity in the absence (dark
bars) and presence (gray bars) of 25 nM α-factor. The assay was repeated three times
with the results normalized to response to α-factor in the absence of the novobiocin
(100%) and reported as mean ± standard error. An asterisk (*) indicates that the results
are signiﬁcantly different (p b 0.01) for activity in the presence and absence of α-factor.
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the 2.5 fold increase with the 11-mer, the [Bio-DOPA]11-mer enhanced
theα-factor response by approximately 2-foldwhen cellswere incubat-
ed with both peptides. These results suggest that modiﬁcation of the
peptide to include DOPA at position 1 and biotin on the ε-amine of
lysine at position 7 only slightly reduced its stimulatory activity. Thus
both the 11-mer and [Bio-DOPA]11-mer appear to function as positive
allosteric modulators.
Novobiocin, an antibiotic produced by the actinomycete Streptomy-
ces niveus, has no structural similarity to the 11-mer peptide (Fig. 1C),
but in previous work it was shown to exhibit weak agonistic activity
in growth arrest assays on a strain of S. cerevisiae that was supersensi-
tive to α-factor [16,17]. Using our yeast strain, which overexpresses
Ste2p-FT-HT, but is not supersensitive to pheromone, we showed that
novobiocin by itself has no measurable, intrinsic agonistic activity at
the levels tested (up to 2.2 mg/disk in growth arrest assays and
37.5 μM in FUS1–lacZ assays). However, when combined with α-factor
(0.1 or 0.2 μg per disk) the presence of novobiocin (2.2 mg/4.5 ml
Noble agar–cell mixture) resulted in an increase in growth arrest activ-
ity (Fig. 3A). In the presence of 0.1 μg/disk α-factor, novobiocin caused
an increase in halo area from 61± 14mm2 to 155± 24mm2. Similarly,
an increase in size (192 ± 11 mm2 to 273 ± 14 mm2) was observed in
the presence of 0.2 μg/disk α-factor and novobiocin. To eliminate the
possibility that the novobiocin effect on halo size was due to the
displacementα-factor from the paper disk rather than allosteric modu-
lation, the experimentwas repeated by spottingα-factor (10 ng) direct-
ly onto the lawn of cells containing novobiocin (2.2 mg/lawn). In the
absence of the paper disk, halo area was increased in the presence of
novobiocin by 45%, thus the allosteric effect was independent of the
paper disk. Novobiocin by itself failed to increase reporter gene activity
at concentrations up 37.5 μM (Fig. 3B). When tested at higher amounts
(up to 400 μM), novobiocin likewise failed to stimulate reporter gene
activity (data not shown). In contrast, in the presence of 25 nMα-factor, the FUS1–lacZ response to novobiocin exhibited a dose-
dependent increase in activity up to 12.5 μM (Fig. 3B). These data indi-
cate, that like the 11-mer and [Bio-DOPA]11-mer, novobiocin enhances
the activity of α-factor in themanner consistent with that for a positive
allosteric modulator.
3.2. Novobiocin does not compete with binding of α-factor to Ste2p or alter
the pheromone's binding afﬁnity
The hallmark of an allosteric modulator is that it exerts its effects via
binding to a non-orthosteric site on the receptor. To determine if
novobiocin might be interacting with Ste2p at an allosteric site, a com-
petition binding assay was completed. In this assay, the ability of novo-
biocin (10−4 M to 10−11 M) to compete with 3H α-factor (5 nM) for
binding to Ste2p-FT-HTwasmeasured. The assay showed that novobio-
cin did not preventα-factor binding to the receptor over a 7 log concen-
tration range (Fig. 4A), representing a 20,000 fold molar excess at the
highest concentration (0.1 mM). The control experiment demonstrated
that non-radioactiveα-factor had a typical binding competition activity
with a Ki value of 4±0.1 nM(Fig. 4A). To determine if novobiocin inﬂu-
enced theα-factor ligand–receptor afﬁnity, anα-factor saturation bind-
ing assay was carried out in the presence and absence of novobiocin at
concentrations ranging from 10−4 M to 10−8 M. Under all condi-
tions tested, the Kd values and maximal binding activity were similar
(p b 0.001) for cells in the absence or presence of novobiocin (Fig. 4B).
These results indicated that novobiocin does not exert its effects by
inﬂuencing the binding ofα-factor to Ste2p. The combination of the re-
sults showing the enhancement of α-factor-dependent activity and the
lack of competition in ligand binding assays places novobiocin in the
category of a positive allostericmodulator, as had been shownprevious-
ly for the 11-mer [14]. The structural dissimilarity between these two
Fig. 4. A. Competition binding for [3H]α-factor (5 nM) in the presence of α-factor
(10−11 M to 10−6 M) or novobiocin (10−11 M to 10−4 M). The data points (±standard
error) represent quadruplicate determinations. B. [3H]α-factor saturation binding assay
conducted in the absence and presence of novobiocin (10−4 to 10−8 M). The data points
(±standard error) represent quadruplicate determinations.
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through the same or different sites on Ste2p.
3.3. [Bio-DOPA]11-mer cross-links into Ste2p and novobiocin inhibits this
cross-linking
To determine whether the [Bio-DOPA]11-mer could be cross-linked
into Ste2p in a manner similar to that accomplished for DOPA-labeled
α-factor [15], cell membranes were incubated with the compound
and cross-linking initiated by the addition of 2 mM sodium periodate.
Under the experimental conditions used our studies, periodate oxida-
tion has been demonstrated to be speciﬁc for molecules containing an
ortho-dihydroxyphenyl ring, such as DOPA [22] and cross-linking only
occurs when the oxidized DOPA intermediate is placed in close proxim-
ity to an amino acid with a suitable side chain via protein–protein inter-
action [26]. Approximately 2 μg of Ste2p-enriched membrane protein
per lane was fractionated by SDS-PAGE and processed for immunoblot-
ting. The western blot showed bands of similar size associated
with Ste2p for membrane preparations incubated with or without
[Bio-DOPA]11-mer (85 μM) and in the presence or absence of novobio-
cin (5mM and 50mM) (Fig. 5, anti-Ste2p). Thus Ste2p-FT-HTwas pres-
ent in all lanes at approximately the same level. An identical blot,
probed with NeutrAvidin-HRP to detect biotin incorporated through
crosslinking of [Bio-DOPA]11-mer (Fig. 5, Biotin Signal) exhibited
bands corresponding to the Ste2p-FT-HT monomer and dimer only for
cells incubated with the [Bio-DOPA]11-mer; in the absence of ligand,
no signal was detected. Incubation with the [Bio-DOPA]11-mer in the
presence of 5 mM or 50 mM novobiocin reduced the labeling to 22%and 7% of the control level, respectively, for the blot in Fig. 5 (26% ±
11% and 11% ± 12% average over 3 replicate blots) suggesting that no-
vobiocin blocked cross-linking of the [Bio-DOPA]11-mer to the receptor.
The presence of 50-fold excess of α-factor did not compete with the
[Bio-DOPA]11-mer in the cross-linking reaction (data not shown).
Previous studies by our lab demonstrated that the 11-mer and
α-factor did not compete for the same binding site [14], thus it was
our hypothesis that α-factor binds to a site distinct from that for the
[Bio-DOPA]11-mer, and would not inhibit cross-linking.
To determine whether novobiocin was being oxidized by the
addition of sodium periodate, a series of 1H and 13C NMR experiments
(Supplementary material: Figs. S1–S8) were conducted using a one-
to-one stoichiometric ratio of 25 mM novobiocin to 25 mM sodium
periodate. No new peaks or changes in relative peak intensities within
the spectrawere noted for either nuclei, which suggests that novobiocin
is stable to periodate oxidation (Supplementary material, compare
Figs. S5 to S7 and S6 to S8) and is not consuming the periodate neces-
sary to oxidize DOPA for the cross-linking reaction.
Using DL-DOPA as a model, an experiment was conducted to deter-
mine if oxidation by sodium periodate can occur in the presence of no-
vobiocin. For this experiment, 16 mM concentrations of each of the
three reagents were used. The novobiocin and periodate solution was
prepared according to the procedure described in the Supplementary
material. Following incubation, a stoichiometric equivalent of the
50 mM DL-DOPA solution was added. After mixing, the solution was
allowed to incubate for 1 h. During incubation, the mixture changed
from the original clear solution to a transparent, dark brown. 1H NMR
spectra were generated to monitor the reactivity of the system, and ox-
idation of DL-DOPA was conﬁrmed by changes in the aromatic region,
which matched those for a one-to-one mixture of 25 mM DL-DOPA
and 25mMperiodatewith no added novobiocin (Supplementarymate-
rial: Figs. S9–S12). In the presence of novobiocin, DOPA is still effectively
oxidized by sodium periodate, therefore, the reduction in [Bio-DOPA]
11-mer cross-linking to Ste2p observed under these conditions is likely
not due to the inhibition of the cross-linking reaction itself.
To examinewhether novobiocin speciﬁcally blocked cross-linking of
the [Bio-DOPA]11-mer to the receptor, we performed a cross-linking re-
action using the [Bio-DOPA]13-mer, a full length α-factor which binds
the orthosteric site of the receptor and retains biological activity [27]
(Fig. 5). After normalization of the Biotin Signal (cross-linked product)
to the anti-Ste2p signal (total receptor present), 5 mM novobiocin did
not inhibit the cross-linking of the [Bio-DOPA]13-mer (136% of control
for the blot presented in Fig. 5, 118% ± 25% average over 3 replicate
blots). In the presence of 50 mM novobiocin, cross-linking was de-
creased slightly to 84% of control levels as determined by normalization
(92% ± 17% average over 3 replicate blots). In contrast, cross-linking of
the [Bio-DOPA]11-mer was reduced to 7% of the control level in the
presence of 50 mMnovobiocin. These data further support our hypoth-
esis that the [Bio-DOPA]11-mer and novobiocin do not interact with the
orthosteric site of Ste2p in the same manner as the orthosteric ligand
α-factor.
To determine if the effect of novobiocin on [Bio-DOPA]11-mer
cross-linking was dose-dependent, cell membranes were incubated
with [Bio-DOPA]11-mer in the presence of increasing concentrations
of novobiocin, ranging from 0.08 mM to 50 mM (Fig. 6A). Cross-
linking of the [Bio-DOPA]11-mer to Ste2p-FT-HT increased as the con-
centration of novobiocin decreased (Biotin Signal, lower panel). The
FLAG blot indicated that there was a slight variation of Ste2p-FT-HT
present in each sample (anti-Ste2p, upper panel), thus the quantitation
of banddensitieswasnormalized by calculating the ratio of Biotin Signal
band density to that of anti-Ste2p signal band density. Novobiocin in-
hibits the cross-linking of the [Bio-DOPA]11-mer in a dose-dependent
manner, with maximal inhibition (~90% reduction) occurring between
10 and 50mM novobiocin. Even at 5:1 and 1:1 molar ratios of novobio-
cin to the crosslinker, 55% and 35% inhibition of crosslinking, respective-
ly, was observed. The potency of novobiocin as an allosteric modulator
Fig. 5.Western blots of Ste2p enriched samples that were probed for Ste2p using an anti-FLAG antibody (anti-Ste2p blots — top panels) and for the receptor–ligand complex using
NeutrAvidin-HRP (Biotin Signal blots — lower panels) when incubated in the presence of [Bio-DOPA]11-mer (85 μM — panels on the left) in the presence or absence of novobiocin
(5 mM and 50 Mm) or [Bio-DOPA]13-mer (10 μM — panels on the right) in the presence or absence of novobiocin (5 mM and 50 mM).
Fig. 6. A. Western blots of FLAG enriched samples probed for Ste2p (upper blot, anti-
Ste2p) and for the receptor–ligand complex (lower blot, Biotin Signal). Membranes
were treated with 85 μM [Bio-DOPA]11-mer in the presence or absence of novobiocin
(0.08mM to 50mM). The values under each lane (percent inhibition of XL)were calculat-
ed by normalizing the Biotin Signal to the anti-Ste2p signal and expressing the normalized
value as percent reduction of cross-linking relative to that in the absence of novobiocin.
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pounds may be interacting with the same site on the receptor.
4. Discussion
Previously, two laboratories showed that the coumarin antibiotic,
novobiocin, acts as aweak agonist of Ste2p, a tridecapeptide pheromone
receptor, in a supersensitive yeast strain [16,17]. We now present evi-
dence that novobiocin can act as a positive allosteric modulator for
Ste2p in a strain that is not supersensitive to the natural ligand. Like-
wise, the C-terminally truncated analogs of α-factor, the 11-mer and
[Bio-DOPA]11-mer, were shown to enhance α-factor's activation of
the receptor in both growth arrest and reporter gene assays, at concen-
trations where neither alone had a measureable effect; these peptides
may be considered to be positive allosteric modulators as well.
Based on saturation and competition binding assays presented here
with novobiocin and in a prior publication from our labwith the 11-mer
[14] it appears that these compounds interactwith a site on the receptor
that is distinct from the orthosteric binding site. Speciﬁcally, neither the
11-mer [14] nor novobiocin (Fig. 4) competed with binding of α-factor
to Ste2p. The results from the cross-linking experiments (Figs. 5 and 6)
show that despite no structural similarity between novobiocin and the
[Bio-DOPA]11-mer, both compounds appear to be competing for inter-
action at the same site on the receptor. Additionally, when present at a
1000-fold molar excess novobiocin did not prevent the cross-linking
of α-factor analog, the [Bio-DOPA]13-mer (Fig. 5) which binds to
the orthosteric site of the receptor [27], whereas ~120-fold molar
excess of novobiocin led to a 90% reduction in the crosslinking of the
[Bio-DOPA]11-mer (Fig. 6). This latter experiment also provides
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prevent the activation of the dihydroxyphenyl moiety. Our NMR results
(Supplementarymaterial) indicate that novobiocin remains intact upon
extended incubation (1 h) with sodium periodate under the same con-
ditions (i.e. buffer and temperature) used for the cross-linking reaction.
However, the possibility remains that a minor degradation product or
other contaminant present in the periodate-treated novobiocin mix-
ture, which was not detected by NMR, might inﬂuence the cross-
linking of the [Bio-DOPA]11-mer or [Bio-DOPA]13-mer to the receptor.
Clearly at 5 mM, this is not the case: novobiocin did not inhibit the
cross-linking of the [Bio-DOPA]13-mer, but did reduce markedly the
cross-linking of the [Bio-DOPA]11-mer. We did observe a slight de-
crease in cross-linking of the [Bio-DOPA]13-mer in the presence of
50 mM novobiocin (to 84% of control level), but it was not as marked
as the decrease in cross-linking observed for the 11-mer (to 7% of
control level). Although visualization of the blot in Fig. 5 suggests that
the decrease in cross-linking of the [Bio-DOPA]13-mer at 50 mM novo-
biocin is greater, quantitation of the band densities using Image Lab
software showed only a minimal drop in cross-linking. It is possible
that at 50 mM novobiocin interaction of this allosteric modulator, or
some associated contaminant,with the receptor could alter the receptor
conformation to inﬂuence binding of the [Bio-DOPA]13-mer at the
orthosteric site.
Since novobiocin clearly acts at a site that is different from the
α-factor binding site, it is reasonable to conclude that [Bio-DOPA]11-
mer also acts at this allosteric site. It is possible, however, that novobio-
cin interactswith a secondallosteric site, and binding to this site induces
a conformational change in the receptor that inhibits the cross-linking
of the [Bio-DOPA]11-mer compound.
Another possibility is that the positive allosteric modulation
observed in this study is mediated through one protomer of a receptor
homodimer or a higher-ordered oligomeric complex. This type of mod-
ulation has been observed for a variety of GPCR constructs exhibiting
negative cooperativity across receptor homodimers, but no examples
of positive allosteric modulation have been clearly demonstrated [28].
A recent study demonstrated that binding of a bitopic allosteric modu-
lator of the dopamine D2 receptor simultaneously to the orthosteric
site and to a secondary binding pocket of one protomer imparted a neg-
ative allosteric effect to the orthosteric site of a second protomer [29].
Interestingly, α-factor binds to the receptor as a bitopic ligand; our
model predicts that the N-terminus of the peptide interacts with recep-
tor TM5–TM6 and is important for receptor activation, while the
C-terminus interacts with TM1 and is important for receptor binding
[27]. It is possible that the 11-mer or novobiocin bind to one protomer
of a receptor dimer inducing a conformational change that causes
α-factor to be active at lower concentrations.
As expected,α-factor did not inhibit cross-linking of [Bio-DOPA]11-
mer as predicted by the lack of competition between the 11-mer and
α-factor for binding [14], further supporting our hypothesis that these
ligands are binding at different sites on the receptor. However, the 11-
mer itself did not inhibit cross-linking of [Bio-DOPA]11-mer to Ste2p
(data not shown). One possibility for this anomalous result is that the
experimental protocol required to obtain crosslinking (30 minute reac-
tion; see Experimental procedures 2.3) favors covalent over non-
covalent interactions. Thus, once the [Bio-DOPA]11-mer is covalently
cross-linked to Ste2p, competition by free 11-mer can no longer occur
despite the fact that the 11-mer concentration of free was greater
than that of the cross-linking ligand. Attempts to carry out the cross-
linking at shorter time periods did not yield enough cross-linked prod-
uct for detection on the western blots.
The 11-mer presents an interesting example of an allostericmodula-
tor in that it is structurally very similar to the orthosteric ligand,
α-factor. In most cases, allosteric modulators are structurally unrelated
to the endogenous ligand and bind to a site that is distinct from that of
the orthosteric site. However, there are accounts of allosteric enhancers
that appear to overlap with residues in the orthosteric binding site[30–32]. Previous experiments have created a model depicting
α-factor activating Ste2p in a two-step interaction. The C-terminal tail
of the peptide binds to the receptor, then orients itself by bending
through the Pro-Gly residues, and activates Ste2p by interaction with
the peptide's N-terminus [33]. Therefore, it seems likely that the
N-terminus of the 11-mer, a structural analog ofα-factor, may partially
overlap with the orthosteric ligand's activation site, but not the binding
site. The exact interactions involved in 11-mer binding require
experiments to identify the DOPA cross-linking site between Ste2p
and [Bio-DOPA]11-mer. These are currently underway.
There are three theories [32] that offer possible explanations as to
how allosteric modulators can overlap in binding with the orthosteric
modulator: (1) Allosteric compounds may be able to overlap with the
orthosteric sites when binding alone, but exploit a different subsite
from the orthosteric siteswhen in the presence of the orthosteric ligand,
(2) allosteric enhancers and orthosteric ligands may bind the receptor
at different points in time depending on the receptor's current ligand-
preferring conformation, and (3) the allosteric and orthosteric modula-
tors could be binding to separate monomeric forms of the receptor that
ultimately form a dimer, one of which is bound to the orthosteric ligand
while the other is bound to the allostericmodulator. At thepresent time,
we cannot distinguish among these models by our data at hand.
In summary, we have found two structurally diverse molecules that
act as positive allosteric modulators for the activation of Ste2p by the
mating pheromoneα-factor. To the best of our knowledge, these mole-
cules represent the ﬁrst allosteric ligands identiﬁed for a Class D (fungal
mating pheromone receptors) GPCR. Furthermore, the yeast system
described in this report could be readily adapted for use as a high-
throughput screen to identify allosteric modulators for mammalian
receptors expressed heterologously in yeast cells. Many mammalian
receptors have been successfully expressed in yeast, and coupled to
the endogenous yeast signaling pathway either directly or by co-
expression of the appropriate cognate mammalian G protein [34,35].
The genetic and molecular tools available for the manipulation of pro-
tein expression in yeast provide an excellentmodel system for the char-
acterization of receptor pharmacology. Further investigation of these
interesting ﬁndings may reveal novel means to regulate GPCR function
for both yeast and mammalian receptors.
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